Ainhoa Bilbao
Ainhoa Bilbao
1Institute of Psychopharmacology, Central Institute of Mental Health, Faculty of Medicine Mannheim, University of Heidelberg, Heidelberg, Germany
1,*,†,
Claus Rieker
Claus Rieker
2Department of Molecular Biology of the Cell I, DKFZ-ZMBH Alliance, German Cancer Research Center, Heidelberg, Germany
2,†,
Nazzareno Cannella
Nazzareno Cannella
1Institute of Psychopharmacology, Central Institute of Mental Health, Faculty of Medicine Mannheim, University of Heidelberg, Heidelberg, Germany
1,
Rosanna Parlato
Rosanna Parlato
2Department of Molecular Biology of the Cell I, DKFZ-ZMBH Alliance, German Cancer Research Center, Heidelberg, Germany
3Institute of Applied Physiology, University of Ulm, Ulm, Germany
4Department of Medical Biology, Institute of Anatomy and Cell Biology, University of Heidelberg, Heidelberg, Germany
2,3,4,
Slawomir Golda
Slawomir Golda
5Department of Molecular Neuropharmacology, Institute of Pharmacology of the Polish Academy of Sciences, Krakow, Poland
5,
Marcin Piechota
Marcin Piechota
5Department of Molecular Neuropharmacology, Institute of Pharmacology of the Polish Academy of Sciences, Krakow, Poland
5,
Michal Korostynski
Michal Korostynski
5Department of Molecular Neuropharmacology, Institute of Pharmacology of the Polish Academy of Sciences, Krakow, Poland
5,
David Engblom
David Engblom
2Department of Molecular Biology of the Cell I, DKFZ-ZMBH Alliance, German Cancer Research Center, Heidelberg, Germany
2,
Ryszard Przewlocki
Ryszard Przewlocki
5Department of Molecular Neuropharmacology, Institute of Pharmacology of the Polish Academy of Sciences, Krakow, Poland
5,
Günther Schütz
Günther Schütz
2Department of Molecular Biology of the Cell I, DKFZ-ZMBH Alliance, German Cancer Research Center, Heidelberg, Germany
2,
Rainer Spanagel
Rainer Spanagel
1Institute of Psychopharmacology, Central Institute of Mental Health, Faculty of Medicine Mannheim, University of Heidelberg, Heidelberg, Germany
1,
Jan Rodriguez Parkitna
Jan Rodriguez Parkitna
2Department of Molecular Biology of the Cell I, DKFZ-ZMBH Alliance, German Cancer Research Center, Heidelberg, Germany
5Department of Molecular Neuropharmacology, Institute of Pharmacology of the Polish Academy of Sciences, Krakow, Poland
2,5
1Institute of Psychopharmacology, Central Institute of Mental Health, Faculty of Medicine Mannheim, University of Heidelberg, Heidelberg, Germany
2Department of Molecular Biology of the Cell I, DKFZ-ZMBH Alliance, German Cancer Research Center, Heidelberg, Germany
3Institute of Applied Physiology, University of Ulm, Ulm, Germany
4Department of Medical Biology, Institute of Anatomy and Cell Biology, University of Heidelberg, Heidelberg, Germany
5Department of Molecular Neuropharmacology, Institute of Pharmacology of the Polish Academy of Sciences, Krakow, Poland
✉*Correspondence: ainhoa.bilbao@zi-mannheim.de
This article was submitted to the journal Frontiers in Behavioral Neuroscience.
†Shared first authorship.
Edited and reviewed by: John D. Salamone, University of Connecticut, USA
Received 2014 Jun 17; Accepted 2014 Jun 19; Collection date 2014.
Keywords: CREB, dominant negative CREB, dopamine receptor D1, activity-dependent gene expression, cocaine-related behavior, addiction
Copyright © 2014 Bilbao, Rieker, Cannella, Parlato, Golda, Piechota, Korostynski, Engblom, Przewlocki, Schütz, Spanagel and Rodriguez Parkitna.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
